secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000520
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta promotes David R. Shook, M.D., to Chief Medical Officer
--------------------------------------------------------------

- Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.
- He has extensive cell therapy development experience, including first-in-human trials with CD19 CAR-NK cells.
- Dr. Shook co-developed the membrane-bound IL-15 component of Nkarta’s NK cell platform.
- He continues as a practicing pediatric oncologist and transplant physician.
- Prior Nkarta, he was at St. Jude Children’s Research Hospital in the lab of scientific founder Dario Campana.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/0000950170-23-000520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/nktx-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer